Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Genomma Lab Internacional Reports First Quarter 2018 Results

Genomma Lab
Posted on: 26 Apr 18

MEXICO CITY, April 25, 2018 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), today announced its results for the first quarter ended March 31, 2018. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS).

The following table provides an abridged Income Statement, in millions of pesos. The margin for each figure represents its ratio to net sales and the percentage change from the first quarter 2018, as compared with the same period in 2017:



% Sales


 % Sales

Var. %

Net Sales






Gross Profit






Operating Income












Net Income







(1) EBITDA is defined as operating income before depreciation and amortization.

Comments from the CEO

Mr. Máximo Juda, Chief Executive Officer, commented: "We are pleased with our progress in the first quarter of 2018. While exchange rate effects on our consolidated figures adversely impacted our first quarter sales growth when expressed in Mexican pesos, year over year sales increased 4.1% in local currencies, with one of the highest quarterly EBITDA margins in our Company's history. This is a reflection of improved fulfillment capabilities as well as our streamlined operations and the continued successful execution of important cost containment strategies throughout our organization."

Mr. Juda continued: "Further, we made important headway in anticipation of launching our new manufacturing facility located in the State of Mexico. We continued to rationalize product portfolio with a focus on our most profitable SKUs, ensuring optimal plant efficiency, and ramped up our innovation progress at the Mexico City pilot plant in anticipation of launches in the second half of the year. Construction of the new production facility is progressing well and remains on track to begin production in the fourth quarter of 2018, to ensure superior product quality and an enhanced value equation, while economies of scale will drive further important cost efficiencies."

For a full version of Genomma Lab Internacional's First Quarter 2018 Earnings Release, please visit: Genomma Lab Internacional Q1 2018 Earnings Release (English version)


Genomma Lab will host a conference call on Thursday, April 26, 2018, to discuss these results at 11:00 a.m. Eastern Time / 10:00 Central Time (Mexico City Time).

To access the call, please dial:
+1 877-407-8031 (From within the U.S.)
+1 201-689-8031 (From outside the U.S.)

There will also be a live Audio Webcast of the event at: 

Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "LABB" (Bloomberg: LABB:MM).

Editor's Details

Mike Wood

Last updated on: 26/04/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.